BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced it will report fourth quarter and year ended December 31, 2013 financial results on Tuesday, March 25, 2014. BIND Therapeutics Inc (NASDAQ:BIND) stock performance was 7.75% in last session and finished the day at $12.93. Traded volume was 259,387million shares in the last session and the average volume of the stock remained 125.91million shares. BIND Therapeutics Inc (NASDAQ:BIND) insider ownership is17.00%.

Oncomed Pharmaceuticals (NASDAQ:OMED) posted its quarterly earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.15 by $0.30, American Banking & Market News reports. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) rose 5.50 percent to $38.00 yesterday on volume of 284,351.00 million shares. The intra-day range of the stock was $34.71 to $38.47. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) has a market capitalization of $1.06 billion.

Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, “Compositions and Methods for Enhancing Immunogenicity of Antigens”. The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028. Advaxis, Inc. (NASDAQ:ADXS)’s stock on Mar20, 2014 reported an increase of 0.61% to the closing price of $4.93. Its fifty two weeks range is $2.60 -$14.25. The total market capitalization recorded $69.08 million. The overall volume in the last trading session was 295,314 million shares. In its share capital, Advaxis, Inc. (NASDAQ:ADXS) has 7.48 million outstanding shares.

The most recent short interest data has been released by the NASDAQ for the 02/14/2014 settlement date, which shows a 372,586 share increase in total short interest for Enzon Pharmaceuticals Inc (NASDAQ:ENZN) to 1,161,223, an increase of 47.24% since 01/31/2014. On Thursday, shares of Enzon Pharmaceuticals Inc (NASDAQ:ENZN) advanced 3.85% to close the day at $1.08. Company return on investment (ROI) is 0.10% and its monthly performance is recorded as 9.09%. Enzon Pharmaceuticals Inc (NASDAQ:ENZN) quarterly revenue growth is -0.92%.